New Meaning for Extended Release
For a drug that Pfizer (PFE) says will be an important addition to its arsenal, Lyrica is getting a slow release in the U.S.
The drug was approved by the Food and Drug Administration on Monday as an add-on treatment for epilepsy, but Pfizer says the product won't be available until this fall. Lyrica also was approved by the FDA in December as a treatment for pain associated with shingles and for nerve pain associated with diabetes. At the time, Pfizer said the drug would reach the market "in the near future."
The drug isn't on the market for any of the FDA-approved uses because it has been declared a controlled substance and must be reviewed and classified by the Drug Enforcement Administration. Rebecca Hamm, a Pfizer spokeswoman, said Monday the company hopes to get the lowest of five DEA classifications, meaning the drug has the least chance for abuse or misuse.
But the DEA hasn't made a decision, and it can take many months to classify a controlled substance. For example, it took nearly four months for the DEA to sign off on the sleep drug Lunesta from Sepracor (SEPR) before the drug became available in the U.S. in early April.Lyrica has been viewed by Pfizer as a successor to Neurontin, which had $2.73 billion in sales last year and which is under ferocious attack by generic competitors. Neurontin is approved for seizures and for pain associated with shingles. During the first quarter of 2005, Neurontin recorded $182 million in worldwide sales, down 74% from the same quarter last year. The U.S. component fared worse: first-quarter 2005 sales dropped 90% to $56 million. Meanwhile, Lyrica produced only $20 million in revenue during the first quarter of 2005, thanks to foreign market sales. Analysts say Lyrica has several advantages over Neurontin -- it can treat more diseases, it's more potent, it has fewer interactions with other drugs, and it's easier to take.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV